Overview

HSV529 Vaccine in HSV-2 Seropositive Adults

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety of HSV529 vaccine in healthy volunteers with HSV infection and to determine if administration of the HSV529 vaccine increases the immune response in genital skin.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Sanofi Pasteur, a Sanofi Company
University of Washington
Treatments:
Valacyclovir